Durect Value Stock - Dividend - Research Selection
Market price: 1,65 USD
Durect Fundamental data and company key figures of the share
|Annual reports in USD|
|Net operating cash flow||-38.704.000|
|Free cash flow||-38.912.000|
|Liabilities & Shareholders equity||75.641.000|
|Diluted shares outstanding||199.457.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||329.104.064,00 USD|
|Raw Data Source||US GAAP in Millionen USD|
Description of the company
Durect Corporation is a specialty pharmaceutical company focused on the development of pharmaceutical products based on its drug delivery technology platforms. The Company´s product pipeline, as of December 31, 2012, consisted of eight investigational drug candidates in clinical development, with one program the subject of a New Drug Application (NDA) with the United States Food and Drug Administration (FDA), with one program in Phase III with an NDA in preparation, two programs in Phase II and three programs in Phase I. The Company´s products candidates include Remoxy, POSIDUR, ELADUR, TRANSDUR-Sufentanil, Relday, ORADUR-based opioid, ORADUR-ADHD, Relday and other products. The Company´s developments are focused on the application of its drug delivery technologies to potential products in a variety of chronic and episodic disease areas, including pain, central nervous system (CNS) disorders, cardiovascular disease and other chronic diseases.